The Danish pharmaceutical giant plans to sell its weight loss drug through American Hims & Hers, according to sources who spoke to Bloomberg.
The two companies had a similar collaboration last year, which Novo Nordisk chose to end after Hims & Hers sold versions of Wegovy. As recently as February of this year, Novo Nordisk sued Hims & Hers for patent infringement.
"We are always in discussions with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These discussions are ongoing," a Novo Nordisk spokesperson said on Friday.
